Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 14Recruiting 9Terminated 7Withdrawn 3Unknown 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 21Lymphoma 18Lymphoma, Large B-Cell, Diffuse 15Leukemia, Myeloid, Acute 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 12Leukemia, Lymphocytic, Chronic, B-Cell 12Multiple Myeloma 11Burkitt Lymphoma 11Leukemia 10Lymphoma, Mantle-Cell 9Myelodysplastic Syndromes 8Melanoma 8Lymphoma, B-Cell, Marginal Zone 7Triple Negative Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Hodgkin Disease 6Carcinoma, Non-Small-Cell Lung 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Sarcoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Myeloid, Chronic-Phase 4

Interventions

Oxaliplatin 20Fluorouracil 20Leucovorin 19Bevacizumab 16Cetuximab 13Irinotecan 12Capecitabine 8regorafenib 5Radiotherapy 5Nivolumab 5Drug Therapy 5aflibercept 4Radiosurgery 4Neoadjuvant Therapy 4Magnetic Resonance Spectroscopy 4Chemotherapy, Adjuvant 4Biopsy 4pembrolizumab 3durvalumab 3atezolizumab 3Specimen Handling 3Folfox protocol 3Cyclophosphamide 3trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2poly(I).poly(c12,U) 2futuximab 2fludarabine 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Colorectal Neoplasms × Cyclophosphamide × Clear all
NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

City of Hope Medical Center

Phase 1 Withdrawn
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

National Institutes of Health Clinical Center (CC)

Phase 2 Withdrawn
Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03169777 2025-02-21

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡